Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

InMed Pharmaceuticals  / Equity Bottom-Up

<ul><li>BayMedica’s VP, Sales &amp; Marketing, Jerry. P. Griffin joined us on The Water Tower Hour.</li><li>Those interested can listen to the podcast on Apple Podcasts, Google Podcasts, Spotify, or our website.</li><li>BayMedica is the commercial business arm of rare cannabinoids-based drug developer InMed Pharmaceuticals.</li></ul>

BayMedica’s VP, Sales &amp; Marketing, Jerry. P. Griffin joined us on The Water Tower Hour.Those interested can listen to the podcast on Apple Podcasts, Google Podcasts, Spotify, or our website.BayMedica is the commercial business arm of rare cannabinoids-based drug developer InMed Pharmaceuticals.

InMed Pharmaceuticals, Inc. - Water Tower Hour Recap

<ul><li>BayMedica reports another strong quarter. The commercial business operating arm of InMed reported revenue of $1.24 million for the quarter ended December 30, 2023, representing a 164% Y/Y increase and 38% Q/Q growth.</li><li>Revenue for the quarter exceeded our estimate of $1.13 million. BayMedica has now recorded quarterly revenue of more than $1 million in three of the last four quarters.</li><li>For the first six months of the current fiscal year ending June 30, 2024, revenue climbed 171% to $2.1 million from $0.8 million in 1HFY23. </li></ul>

BayMedica reports another strong quarter. The commercial business operating arm of InMed reported revenue of $1.24 million for the quarter ended December 30, 2023, representing a 164% Y/Y increase and 38% Q/Q growth.Revenue for the quarter exceeded our estimate of $1.13 million. BayMedica has now recorded quarterly revenue of more than $1 million in three of the last four quarters.For the first six months of the current fiscal year ending June 30, 2024, revenue climbed 171% to $2.1 million from $0.8 million in 1HFY23. 

InMed Pharmaceuticals, Inc. - Revenues Flowing, Drug Development Pipeline Advancing

<ul><li>Building on a year of progress. Following a banner year for InMed in 2023, including significant advancement and expansion of its rare cannabinoids-focused pharmaceuticals development programs and a breakout year for BayMedica’s commercial operations, the company has laid out its strategic priorities for 2024.</li><li>Advancing a potentially novel approach to treating Alzheimer’s.</li><li>In October 2023, InMed took a significant step forward in its INM-900 series program targeting neurodegenerative diseases after confirming that it has made its final selection of a lead Alzheimer’s disease drug candidate.</li></ul>

Building on a year of progress. Following a banner year for InMed in 2023, including significant advancement and expansion of its rare cannabinoids-focused pharmaceuticals development programs and a breakout year for BayMedica’s commercial operations, the company has laid out its strategic priorities for 2024.Advancing a potentially novel approach to treating Alzheimer’s.In October 2023, InMed took a significant step forward in its INM-900 series program targeting neurodegenerative diseases after confirming that it has made its final selection of a lead Alzheimer’s disease drug candidate.

InMed Pharmaceuticals, Inc. - Strategic Priorities Laid Out for 2024

<ul><li>Unveiling INM-089 targeting AMD. InMed is expanding its rare cannabinoid cannabinol (CBN)-based ocular disease treatment pipeline with INM-089, targeting age- related macular degeneration (AMD).</li><li>INM-089, a CBN analog, is InMed’s second ocular pharmaceutical program, with the company currently engaged in pre-clinical studies of INM-088, investigating its effects in the treatment of glaucoma.</li><li>InMed’s ocular programs target leading causes of severe eyesight loss and blindness.</li></ul>

Unveiling INM-089 targeting AMD. InMed is expanding its rare cannabinoid cannabinol (CBN)-based ocular disease treatment pipeline with INM-089, targeting age- related macular degeneration (AMD).INM-089, a CBN analog, is InMed’s second ocular pharmaceutical program, with the company currently engaged in pre-clinical studies of INM-088, investigating its effects in the treatment of glaucoma.InMed’s ocular programs target leading causes of severe eyesight loss and blindness.

InMed Pharmaceuticals, Inc. - Expands Ocular Disease Treatment Pipeline

<ul><li>BayMedica registers strong Y/Y growth. Although BayMedica reported a 61% decline in sequential revenue in the opening quarter of its new fiscal year ending June 30, 2024, the $902K in sales reported for 1QFY24 was nevertheless almost triple the $321K generated in the year-ago quarter.</li><li>The immaturity of rare cannabinoids ingredients market for health &amp; wellness products makes it difficult to determine definitively any seasonality in the business.</li><li>However, it should not go unnoticed that the sequential sales drop in the latest summer quarter does repeat the pattern reported in 1QFY23 when sequential sales at BayMedica declined by almost 40%. </li></ul>

BayMedica registers strong Y/Y growth. Although BayMedica reported a 61% decline in sequential revenue in the opening quarter of its new fiscal year ending June 30, 2024, the $902K in sales reported for 1QFY24 was nevertheless almost triple the $321K generated in the year-ago quarter.The immaturity of rare cannabinoids ingredients market for health &amp; wellness products makes it difficult to determine definitively any seasonality in the business.However, it should not go unnoticed that the sequential sales drop in the latest summer quarter does repeat the pattern reported in 1QFY23 when sequential sales at BayMedica declined by almost 40%. 

InMed Pharmaceuticals, Inc. - 1QFY24 Review: Pharmaceutical Advances Continue

Canada

InMed Pharmaceuticals Inc. is a biopharmaceutical company. The Company develops cannabis-based botanical and non-botanical therapies through research and development into the extensive pharmacology of cannabinoids. InMed Pharmaceuticals focuses on its proprietary platform technology, drug discovery, and commercialization development.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

InMed Pharmaceuticals (INM US)

InMed Pharmaceuticals, Inc. - Water Tower Hour Recap

BayMedica’s VP, Sales & Marketing, Jerry. P. Griffin joined us on The Water Tower Hour. Those interested can listen to the podcast on Apple...

Water Tower Research

InMed Pharmaceuticals, Inc. - Revenues Flowing, Drug Development Pipeline Advancing

Revenue for the quarter exceeded our estimate of $1.13 million. BayMedica has now recorded quarterly revenue of more than $1 million in three of...

Water Tower Research

InMed Pharmaceuticals, Inc. - Strategic Priorities Laid Out for 2024

These will encompass drug distribution, metabolism, and active pharmaceutical ingredient (API) and drug product formulation/manufacturing.

Water Tower Research

InMed Pharmaceuticals, Inc. - Expands Ocular Disease Treatment Pipeline

Unveiling INM-089 targeting AMD. InMed is expanding its rare cannabinoid cannabinol (CBN)-based ocular disease treatment pipeline with INM-089,...

Water Tower Research

InMed Pharmaceuticals, Inc. - 1QFY24 Review: Pharmaceutical Advances Continue

The immaturity of rare cannabinoids ingredients market for health & wellness products makes it difficult to determine definitively any seasonality...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)